Free Trial

Roche Holding AG (OTCMKTS:RHHBY) Stock Has Average Target Price of $60.00 According to Analysts

Roche logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst consensus is “Moderate Buy”, with eight buy ratings and six hold ratings among 14 analysts; the average one-year price target is $60.00.
  • Recent analyst views were mixed: Morgan Stanley and Deutsche Bank upgraded Roche, while UBS downgraded it to hold; other firms maintained or raised ratings to hold.
  • Roche shares opened at $59.37, close to the consensus target, and several institutional investors reported increasing or initiating positions.
  • MarketBeat previews the top five stocks to own by December 1st.

Shares of Roche Holding AG (OTCMKTS:RHHBY - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the fourteen ratings firms that are covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $60.00.

A number of research firms have recently weighed in on RHHBY. Morgan Stanley upgraded shares of Roche from an "equal weight" rating to an "overweight" rating and set a $63.00 price target on the stock in a report on Friday, August 7th. HSBC restated a "hold" rating on shares of Roche in a research report on Thursday, September 10th. UBS Group cut Roche from a "strong-buy" rating to a "hold" rating in a report on Monday, November 2nd. Zacks Research raised Roche from a "strong sell" rating to a "hold" rating in a report on Monday, August 24th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Roche from a "hold" rating to a "buy" rating in a research report on Friday, October 23rd.

Read Our Latest Research Report on Roche

Institutional Trading of Roche

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. S&CO Inc. raised its position in shares of Roche by 163.0% during the 1st quarter. S&CO Inc. now owns 140,551 shares of the company's stock worth $6,880,000 after purchasing an additional 87,107 shares during the last quarter. Opal Capital LLC bought a new position in shares of Roche during the 1st quarter worth approximately $4,448,000. First Command Advisory Services Inc. raised its position in Roche by 188.7% in the 3rd quarter. First Command Advisory Services Inc. now owns 37,694 shares of the company's stock valued at $1,956,000 after buying an additional 24,639 shares during the last quarter. Associated Banc Corp acquired a new stake in Roche in the third quarter valued at about $1,740,000. Finally, GAMMA Investing LLC lifted its position in Roche by 15.3% in the 3rd quarter. GAMMA Investing LLC now owns 33,458 shares of the company's stock valued at $1,736,000 after acquiring an additional 4,443 shares in the last quarter.

Roche Stock Down 0.1%

Shares of RHHBY opened at $59.37 on Friday. The stock has a 50 day moving average price of $55.86 and a 200 day moving average price of $53.88. The company has a current ratio of 1.23, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. Roche has a one year low of $41.43 and a one year high of $61.49.

Roche Company Profile

(Get Free Report)

Roche is a Swiss healthcare company with two main businesses: pharmaceuticals and diagnostics. Founded in Basel in 1896, the company develops and commercializes medicines and provides diagnostic tests, instruments, and digital health solutions.

Its pharmaceutical research and products span areas including oncology, immunology, neuroscience, ophthalmology, and infectious diseases. Its diagnostics business serves clinical laboratories, hospitals, healthcare providers, and patients with tools used to detect and monitor a range of medical conditions.

Headquartered in Basel, Roche operates in markets around the world.

Further Reading

Analyst Recommendations for Roche (OTCMKTS:RHHBY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Roche Right Now?

Before you consider Roche, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.

While Roche currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines